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delivered guidance on ﬁ ve of these, with three being recommended. In Australia, 10/21 
of these drugs had licensing approval and seven underwent assessment by the Phar-
maceutical Beneﬁ ts Advisory Committee. All seven received approval for listing on the 
public reimbursement scheme. Similarly, CADTH assessed 16 drugs by HS in 2004. 
Of these, 10 received licensing approval but only one gained approval to be listed by 
the Canadian Expert Drug Advisory Committee. Of these 16 drugs, 14 had licensing 
approval in Australia and 12 underwent assessment by the PBAC, with only two being 
declined approval for listing on the public reimbursement scheme. CONCLUSIONS: 
The current process of pharmaceutical assessment appears to give Australian patients 
timely access to publicly funded pharmaceuticals and that the introduction of HS for 
new and emerging drugs would neither decrease the time to access for patients or 
better inform policymakers than the system already in place. 
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OBJECTIVES: To determine the cost-effectiveness of interventions to reduce road 
trafﬁ c injuries caused by driving under the inﬂ uence of alcohol in Thailand. 
METHODS: This study used generalized cost-effectiveness analysis. We calculated 
costs from a health sector perspective. The time-horizon for intervention implementa-
tion was 1 year with health outcomes measured over a lifetime. The model covers 
road trafﬁ c crash victims who were injured, disabled, or died due to road trafﬁ c 
crashes. We obtained proportions of alcohol-related crashes, by age and sex of the 
victims, from the Thai Injury Surveillance system. Random breath testing (RBT), 
selective breath testing (SBT) and mass media campaigns compared to a “do nothing” 
scenario. We calculated intervention costs and cost offsets of prevented treatment costs 
in 2004 Thai Baht and measured beneﬁ ts in terms of disability-adjusted life-years 
(DALYs) averted. RESULTS: The study found similar incremental cost-effectiveness 
ratios (ICERs) of SBT and RBT. SBT was cost saving while RBT had an ICER of 1000 
Baht (95% uncertainty interval [UI]: cost saving to 7200) per DALY averted if cost-
offsets are included. The ICER of mass media campaigns was 8300 (95% UI: cost 
saving to 45,100). A combination of SBT or RBT and mass media campaigns is very 
cost-effective compared to a willingness to pay threshold of one times gross domestic 
product per capita (110,000 Baht) in 2004. CONCLUSIONS: The result shows all 
interventions are cost-effective, but wide variation is seen in the uncertainty ranges. 
Sobriety checkpoints and mass media campaigns reduce burden of alcohol-related RTI 
by 38,000 to 41,000 DALYs. 
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OBJECTIVES: To determine the cost-effectiveness of routine administration, irrespec-
tive of blood pressure, of a ﬁ xed-dose combination of perindopril and indapamide to 
patients with Type 2 diabetes. METHODS: Prospective cost-effectiveness analysis 
within a 20 country randomized trial of 11,140 patients with Type 2 diabetes random-
ized to perindopril plus indapamide or placebo. We calculated cost per death averted 
at 4.3 years average follow-up and estimated cost per life-year gained by extrapolation. 
RESULTS: The ADVANCE trial showed a 14% relative risk reduction in all cause 
mortality (P < 0.03) and an 18% relative risk reduction (0.8% absolute reduction) in 
cardiovascular mortality (P < 0.03). Hospital admissions for coronary heart disease 
and coronary revascularization were reduced by 5%. Per patient perindopril-indap-
amide cost AUS$1368, but reduced total hospitalization costs by AUS$410 and other 
medication costs (mainly other blood pressure lowering drugs) by AUS$332. Quality 
of life, measured by the EQ-5D, was 0.80 (on a 0–1 scale); with no difference between 
groups. Absolute reduction in all-cause mortality was 1.1%, giving a cost per life saved 
of AUS$49,200, and life-time extrapolation estimated a cost per life-year saved of 
AUS$8,470 (discounted at 3%). CONCLUSIONS: The combination of perindopril 
and indapamide in patients with type 2 diabetes reduces all-cause mortality and 
appears cost-effective. 
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BACKGROUND: Health technology assessment is a pivotal tool to assist policymak-
ers to decide whether a health technology is efﬁ cient. However, the accessibility of 
health technology assessment information in Thailand is problematic. Attempts to 
develop Thai health technology assessment database has been raised. The database 
aims to increase accessibility and utility to policymakers, researchers and practitioners. 
From January 2008, Thai health technology assessment database has been available 
online at http://www.db.hitap.net. OBJECTIVES: The objectives of this study are to 
determine current contents of the database and evaluate the usefulness of the database. 
METHODS: A review of the Thai health technology assessment database was con-
ducted to determine the main characteristics of studies, the number of included studies, 
the number of database members, and number of visitors. Moreover, the use of the 
database was evaluated by an electronic mail survey to 260 website members. 
RESULTS: By the end of 2009, the database consisted of 732 articles including three 
types of studies, 155 full economic evaluation studies, 471 randomized control trials 
studies and 106 quality of life studies. The number of database members is 711. The 
number of visitors increases from 1123 to 1717 hits per month in 2008 and 2009, 
respectively. For the survey results, of 260 members, 41 respondents (15.77%) replied 
to the electronic mail survey. Most of them used the database for studying and/ or 
conducting a research. The usefulness of the database was found most in 65.86% of 
respondents. CONCLUSIONS: Thai health technology assessment database provided 
useful information to users. However, some types of studies should be included to 
support potential users’ needs. Moreover, the registration system for the members 
should be further improved to follow up and effectively disseminate information to 
users. 
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OBJECTIVES: Streptococcus pneumonia can cause invasive diseases such as menin-
gitis and bacteremia, and noninvasive diseases such as pneumonia and acute otitis 
media (AOM), leading to high morbidity and mortality in infants and the elderly. 
Limited data are available for the burden of these diseases in Taiwan. This study 
investigates economic and clinical burden of pneumococcal diseases and AOM in 
Taiwan. METHODS: A retrospective population-based National Health Insurance 
Reimbursement Database (NHIRD) study was performed to estimate the incidence 
and direct medical costs of pneumococcal meningitis/bacteremia/pneumonia and 
AOM from 2002 to 2007 from healthcare provider perspective, including only NHI-
covered costs. RESULTS: The incidence of pneumococcal meningitis is 0.1 per 
100,000 and highest at age <1 (2.4 per 100,000) and decreases with age. The incidence 
of pneumococcal bacteremia is 0.9 per 100,000 with peak at 7.1 per 100,000 at age 
75 and above, followed by 3.7 at age 2 and 3. The incidence of pneumococcal pneu-
monia is 165.1 per 100,000 with peak at 1060.9 per 100,000 at age 75 and above, 
followed by 1230.7 per 100,000 at age 1, followed by 1076.9 per 100,000 at age 2. 
The AOM incidence is 2,729.1 per 100,000 with peak at 23,078.8 per 100,000 at 
age 1, and high in children group (9,641 per 100,000 at age 12 and below). Annually, 
120 deaths are estimated to cause by pneumococcal diseases. The total annual medical 
cost is US$110,886,546. The annual cost for pneumococcal meningitis is US$193,021, 
mainly for inpatients (US$189,794). The annual cost for pneumococcal bacteremia is 
US$744,573, mainly for inpatients (US$732,282). For pneumococcal pneumonia, the 
total annual cost is US$74,029,821 mainly for inpatients (US$66,353,242). For AOM, 
the annual cost is US$35,919,131, US$18,059,540 for inpatients and US$17,859,590 
for out-patients. CONCLUSIONS: Our study shows huge burden of pneumococcal 
diseases and AOM in Taiwan. Prevention of these diseases will help reduce clinical 
and economic burden. 
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OBJECTIVES: To evaluate the cost-effectiveness of different strategies to control 
tuberculosis (TB) in Thailand. METHODS: Strategies included directly observed treat-
ment (DOT) by a health worker, community member, or family member, and a mobile 
phone “contact-reminder” system, compared to self-administered treatment (SAT). 
Cost-effectiveness analysis was undertaken using a decision tree model, which had 
three stages of treatment; initial treatment, re-treatment, and multi-drug resistant TB 
(MDR-TB) treatment. Costs (2005 international dollars: I$) were calculated based on 
treatment periods and treatment outcomes. Health outcomes were estimated over the 
lifetime of smear-positive pulmonary TB patients in disability-adjusted life-years 
(DALYs). Both costs and health outcomes were discounted at 3%. RESULTS: Cost-
effectiveness results did not clearly indicate a preference for any of the interventions 
analyzed. Although the median cost-effectiveness ratio for each DOT intervention was 
favorable, the uncertainty ranges surrounding the health beneﬁ ts were wide, including 
a sizeable probability that SAT could lead to more health gain than DOT strategies. 
The health gain in DALY for family-member DOT was 9400 DALY (95% uncertainty 
interval −7200 to 25,000), for community-member DOT was 13,000 (−21,000 to 
37,000) and health-worker DOT was 7900 (−50,000 to 43,000). There were cost-
savings (from less re-treatment or MDR-TB treatment) associated with family-member 
DOT (–I$9 million (–I$12 million to –I$5 million)) as the trial treatment failure rate 
was signiﬁ cantly lower than for SAT. The mobile phone reminder system was not 
cost-effective, as the mortality rate in the small trial of this intervention was much 
